Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesRisk of tumour progression in early-stage hepatocellular carcinoma after radiofrequency ablation
British Journal of Surgery, 06/25/09
Fernandes ML et al. - In a study to quantify the risk of tumour progression beyond the Milan criteria following radiofrequency (RF) ablation for hepatocellular carcinoma (HCC) and to identify factors associated with tumour progression, this study provides clinicians with an objective risk of tumour progression beyond the Milan criteria after RF ablation at multiple time points. Primary technique failure is identified as a risk factor for tumour progression.
Methods- 111 pts (136 tumours) with liver cirrhosis undergoing RF ablation for HCC within Milan criteria were enrolled.
- Data were analysed retrospectively from a prospectively collected database.
- Cumulative probability of tumour progression beyond the Milan criteria at 6, 12, 18, 24 and 36 mos of RF ablation was 6.4, 11.0, 16.1, 21.2, and 44.8% respectively.
- On multivariable analysis, factors independently associated with tumour progression were failure to achieve primary technique effectiveness, α-fetoprotein level >200 ng/ml, and Child-Pugh grade B cirrhosis.
- Failure to achieve primary RF ablation technique effectiveness was associated with tumour location in segment VIII, a cool-down temperature of 70 °C or less, and multiple overlapping ablations.
Today in Hepatobiliary/Pancreas...keeping you current
Receive free subspecialty "5-minute updates" via email
Surgical management of hepatocellular carcinoma: Is the jury still out
Surgical Oncology, 11/05/09
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials
British Journal of Cancer, 11/13/09
Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report
World Journal of Surgical Oncology, 11/09/09
Sponsor
Article Search
Sponsor
Sponsor